Nanoparticle delivery for transdermal HRT

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue SUPPL. 1, 2012, Pages

  Valenzuela, Pilar ^a   Simon, James A ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Drug delivery; Nanoparticles; Transdermal hormone therapy

Indexed keywords

ADVERSE EFFECT; CONTROLLED TRIAL; DRUG ADMINISTRATION; EMERGING TECHNOLOGIES; HORMONE THERAPY; MEDICAL PRODUCTS; MENOPAUSAL SYMPTOMS; MICELLAR NANOPARTICLES; NANOPARTICLE TECHNOLOGIES; PERMEATION ENHANCERS; PHYSICAL AND CHEMICAL PROPERTIES; PLACEBO GROUPS; POSTMENOPAUSAL WOMEN; SUBCUTANEOUS IMPLANTS; TRANSDERMAL; TRANSDERMAL DELIVERY; TRANSDERMAL DRUG DELIVERY;

CHEMICAL PROPERTIES; DRUG DELIVERY; EMULSIFICATION; MEDICAL NANOTECHNOLOGY; METABOLISM; PHYSIOLOGY;

NANOPARTICLES;

ANTICONVULSIVE AGENT; ESTRADIOL; ESTRONE; NANOPARTICLE; PLACEBO;

ABDOMINAL PAIN; AEROSOL; APPLICATION SITE IRRITATION; BLISTER; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SAFETY; DRY SKIN; EMULSION; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GEL; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMPLANT; LIVER METABOLISM; LOTION; MENOPAUSAL SYNDROME; MICELLAR NANOPARTICLE ESTRADIOL EMULSION; NANOTECHNOLOGY; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN IRRITATION; SKIN REDNESS; TATTOOING; TREATMENT DURATION; VAGINA RING; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; ANIMALS; DRUG DELIVERY SYSTEMS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; NANOPARTICLES;

EID: 84865589911     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.05.008     Document Type: Review

References (42)

1. Simon J.A., ESTRASORB® Study Group Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause 2006, 13(2):222-231.
2. Wagner V., Dullaart A., Bock A.K., Zweck A. The emerging nanomedicine landscape. Nat Biotechnol 2006, 24(10):1211-1217.
3. Moon J.J., Suh H., Bershteyn A., et al. Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses. Nat Mater 2011, 10(3):243-251.
4. Teo M.A., Shearwood C., Ng K.C., Lu J., Moochhala S. In vitro and in vivo characterization of MEMS microneedles. Biomed Microdevices 2005, 7(1):47-52.
5. Menon G.K. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev 2002, 54(Suppl. 1):S3-S17.
6. Desai P., Patlolla R.R., Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Mol Membr Biol 2010, 27(7):247-259.
7. Kumar R., Philip A. Modified transdermal technologies: breaking the barriers of drug permeation via the skin. Trop J Pharm Res 2007, 6(1):633-644.
8. Nelson H.D. Commonly used types of postmenopausal estrogen for treatment of hot flashes: scientific review. JAMA 2004, 291(13):1610-1620.
9. Rossouw J.E., Prentice R.L., Manson J.E., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297(13):1465-1477.
10. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990, 592:52-86.
11. Grady D. Clinical practice. Management of menopausal symptoms. New Engl J Med. 2006, 355(22):2338-2347.
12. Sturdee D.W., Pines A., International Menopause Society Writing Group Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011, 14(3):302-320.
13. Cauley J.A., Robins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative randomized trial. JAMA 2003, 290:1729-1738.
14. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., Allan J.D. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002, 288(7):872-881.
15. Haas J.S., Kaplan C.P., Gerstenberger E.P., Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004, 140(3):184-188.
16. Writing Group for the Women's Health Initiative Investigator Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
17. The Women's Health Initiative Steering Committee Effects of conjugated equine estrogens in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004, 291(14):1701-1712.
18. Notelovitz M., Mattox J.H. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol. Menopause 2000, 7:310-317.
19. Suhonen S.P., Allonen H.O., Lahteenmaki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995, 172:562-567.
20. Buckler H., Al-Azzawi F. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. Br J Obstet Gynaecol 2003, 110:753-759.
21. Bacchi-Modena A., Bolis P., Campagnoli C., et al. Efficacy and tolerability of Estraderm MX, a new estradiol matrix patch. Maturitas 1997, 27:285-292.
22. Archer D.F. Percutaneous 17β-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women. Menopause 2003, 10:516-521.
23. Buster J.E., Koltun W.D., Pascual M.L.G., Day W.W., Peterson C. Low-dose estradiol spray to treat vasomotor symptoms. Obstet Gynecol 2008, 111:1343-1351.
24. Shifren J.L., Rifai N., Desindes S., McIlwain M., Doros G., Mazer N.A. A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. J Clin Endocrinol Metab 2008, 93(5):1702-1710.
25. Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005, 8(Suppl. 1):3-63.
26. Canonico M., Oger E., Plu-Bureau G., et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007, 115(7):840-845.
27. Canonico M., Fournier A., Carcaillon L., et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010, 30(2):340-345.
28. Olié V., Plu-Bureau G., Conard J., Horellou M.H., Canonico M., Scarabin P.Y. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause 2011, 18(5):488-493.
29. Renoux C., Dell'aniello S., Garbe E., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010, 340:2519.
30. Järvinen A., Nykanen S., Paasiniemi L. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. Maturitas 1999, 32:103-113.
31. Järvinen A., Bäckström A., Elfström C., Viitanen A. Comparative absorption and variability in absorption of estradiol from a transdermal gel and a novel matrix-type transdermal patch. Maturitas 2001, 38(2):189-196.
32. Järvinen A., Granander M., Nykänen S., Laine T., Geurts P., Viitanen A. Steady-state pharmacokinetics of oestradiol gel in post-menopausal women: effects of application area and washing. Br J Obstet Gynaecol 1997, 104(Suppl. 16):14-18.
33. Cedars M.I., Judd H.L. Non-oral routes of estrogen administration. Obstet Gynecol Clin North Am 1987, 14:269-298.
34. Kayser J., Ettinger B., Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause 2001, 8(5):328-332.
35. Archer D.F., Furst K., Tipping D., Dain M.P., Vandepol C.A. randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet Gynecol 1999, 94:498-503.
36. Wright DC, inventer; Novavax Inc. assignee. Micellarnanoparticles. US patent 5,629,021; May 13, 1997.
37. Lee R. Micellar nanoparticles: applications for topical and passive transdermal drug delivery. Handbook of non-invasive drug delivery systems 2010, 37-58. Elsevier, Burlington, MA. Kulkarni (Ed.).
38. Ostwald W. Lehrbuchder allgemeinen chemie: part 1 1896, vol. 2. Leipzig, Germany.
39. ®, a topical lotion for treatment of postmenopausal vasomotor symptoms [Abstract]. J Soc Gynecol Invest 2002, 9(Suppl.):238A. [Abstract 533].
40. Dunn L.B., Damesyn M., Moore A.A., Reuben D.B., Greendale G.A. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I). Arch Dermatol 1997, 133(3):339-342.
41. Verdier-Sévrain S., Bonté F., Gilchrest B. Biology of estrogens in skin: implications for skin aging. Exp Dermatol 2006, 15(2):83-94.
42. Taylor M.B., Gutierrez M.J. Absorption, bioavailability, and partner transfer of estradiol from a topical emulsion. Pharmacotherapy 2008, 28(6):712-718.